A phase II study of Erlotinib for patients previously treated non-small cell lung cancer with epidermal growth factor receptor mutatio

Phase 2

• Conditions: non-small cell lung cancer

• Registration Number: JPRN-UMIN000004563
• Lead Sponsor: Fukushima Medical University, cancer center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-11-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis. 2)Patients with massive pleural or pericardial effusion,or ascites. 3)Patients with active severe infections 4)Cases with past history of administration of HER related agents 5)Impossible cases with oral administration 6)Patients with active opthalmological disease 7)Patients with current or previous (within one year) history of gastrointestinal perforation 8)Patients with uncontrollable gastrointestinal ulceration 9)Pregnancy or lactation 10)Patients with symptomatic brain metastasis 11)Patients with active concomitant malignancy 12)Patients with uncontrollable diabetes mellitus 13)Patients with uncontrollable complications 14)Inappropriate patients for this study judged by the physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response rate

Secondary Outcome Measures

Name	Time	Method
desease control rate, progression-free survival, overall survival, safety